CBER lists June 2026 approval letter for Grifols' Procleix Ultrio Elite donor screening assay

What happened

On 29 October 2026, FDA's Center for Biologics Evaluation and Research (CBER) updated its product page for the Procleix Ultrio Elite Assay, a nucleic acid test from Grifols used in donor screening. The page now lists a June 2026 approval letter alongside the product's earlier approvals. It describes the indication as covering blood, plasma, organ and tissue donors.

The entry is thin. The record does not say what the June 2026 letter approved, whether it was a new claim, a change to the testing platform, a labeling update or something else. It also does not say whether the letter changed the donor populations or specimen types covered. Teams should not read more into the update than the page supports. The practical step is to open the letter itself on the CBER page and compare it with the previous approvals listed there.

Why it matters

Donor screening assays sit at the base of the blood and tissue safety system. Blood establishments, plasma collectors and organ and tissue programs rely on a small set of approved tests, and the exact wording of an indication determines where a test can be used and how a facility's procedures and validation documents have to describe it. A new approval letter is therefore worth reading even when the headline claim looks unchanged.

The listed indication spans blood, plasma, organ and tissue donors. Those settings differ in specimen handling, timelines and operating conditions. Anyone who uses or supplies such an assay in more than one setting should check which of those uses the current approval documents actually cover.

Regulatory context: lifecycle paperwork is the story

CBER regulates donor screening tests as biologics-related products. Approved products accumulate letters over time, and each one can alter the approved conditions of use. The CBER page works as the public index of that history. Quality and regulatory teams can use it as a checkpoint against their own controlled documents, because a mismatch between what a facility cites and what the agency lists is an avoidable inspection finding.

Other items from the same days point to the same theme of managing change after approval. FDA's guidance on essential drug delivery performance information, issued on 29 October, covers what data sponsors should submit for devices and drug-device combination products. It applies to investigational, marketing and post-market change applications. It concerns a different product class from donor screening assays, but it shows that the agency expects performance data to be traceable through post-market changes.

Health Canada's 28 October recall of Siemens Healthineers MR and PET/MR systems shows how a software-level error can have clinical consequences. The reported syngo.via MR Flow Quantification issue truncates the final cardiac phase and systematically underestimates flow parameters in retrospectively gated 2D data. Software and algorithm changes in diagnostic products need the same disciplined change control as hardware or chemistry changes.

Who is affected

Blood centers, plasma collection organizations, and organ and tissue programs that use the assay are the most directly affected. So are their quality assurance and regulatory staff, who maintain procedures, validation records and supplier files. For Grifols' customers, the open question is whether the June 2026 letter requires any change to their own validation or procedures. The record does not answer that, so they should confirm it with the manufacturer or the letter itself.

Diagnostics developers more broadly may note a contrast. On 28 October Labcorp said FDA approved its PGDx elio tissue complete test as a companion diagnostic to help identify patients with advanced melanoma. That is a different pathway and purpose, since it is a therapy-linked test rather than a safety screen. Both cases show that approved diagnostics are managed through a record of agency letters that has to be tracked after launch.

What to watch

First, whether CBER or Grifols says more about the substance of the June 2026 approval. The record contains no statement from either, so the scope of the change is not yet known.

Second, whether labeling or instructions for use are revised in step with the letter, and how quickly users receive them.

Third, a broader point about information flow. Some administrative changes elsewhere also depend on timely updating of public records. Italy's AIFA has begun reviewing long-running monitoring registries to decide whether they should be revised or closed, with closures to be announced on its website. From 1 November, Slovakia limits supply-interruption notifications to 60 days and requires MAHs to restate reasons and expected restocking dates when re-notifying. In both cases, regulators are checking whether old records still reflect current reality, and companies should expect similar scrutiny of their own files.